Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
196.00
-0.39 (-0.20%)
At close: May 29, 2026, 4:00 PM EDT
195.23
-0.77 (-0.39%)
After-hours: May 29, 2026, 7:43 PM EDT
Biogen Employees
Biogen had 7,500 employees as of December 31, 2025. The number of employees decreased by 105 or -1.38% compared to the previous year.
Employees
7,500
Change (1Y)
-105
Growth (1Y)
-1.38%
Revenue / Employee
$1,324,987
Profits / Employee
$182,920
Market Cap
28.94B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,500 | -105 | -1.38% |
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
BIIB News
- 3 days ago - Biogen price target raised to $227 from $222 at RBC Capital - TheFly
- 3 days ago - Italy's antitrust regulator opens probe into US Biogen over alleged dominant position - Reuters
- 8 days ago - Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish - MarketBeat
- 8 days ago - Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
- 8 days ago - Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints - TheFly
- 8 days ago - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease - GlobeNewsWire
- 15 days ago - Biogen resumed with an Outperform at Evercore ISI - TheFly
- 15 days ago - Biogen price target raised to $225 from $214 at Piper Sandler - TheFly